Relay Therapeutics’ Bergstrom sells 10,269 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. (RLAY) President, R&D Donald A. Bergstrom sold 10,269 common shares on November 18, 2026, at a weighted average sale price of $16.51 per share; individual trades ranged from $16.30 to $16.99. The sale was made under a Rule 10b5-1 trading plan adopted October 30, 2025. After the sale, he reported 386,609 direct shares, including 5,013 shares underlying restricted stock units.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 10,269 | $16.51 | $170K |
Footnotes (3)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $16.30 to $16.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. Includes 5,013 shares underlying restricted stock units.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
restricted stock units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.